Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison
NCT ID: NCT00767975
Last Updated: 2010-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2384 participants
INTERVENTIONAL
2008-01-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
No interventions assigned to this group
1
Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
isoniazid , randomized, open label
isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
rifampin, randomized, open label
rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
isoniazid , randomized, open label
isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
rifampin, randomized, open label
rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National Taiwan University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li-Min Huang, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
National University Hospital, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Prison
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012 May;16(5):633-8. doi: 10.5588/ijtld.11.0504. Epub 2012 Mar 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOH-97-DC-1502
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
200707047M
Identifier Type: -
Identifier Source: org_study_id